Clinical Trial Search

Primary: Co-Primary Measures: Percent of Patients With at Least a 50% Decrease in Likert Pain Scale From Baseline to Week 12 Follow Up and Percent of Patients That Quit — 34; 29…

Primary: Percentage of Subjects With Therapeutic Cure at 28 Days for All-Analysis Population — 9; 9; 11; 10 Participants

Primary: Percentage of Participants With Change of Treated Lesions — 44; 44; 13 % of participants

Primary: Number of Patients With Neuropathy Grade 2 or Higher (According to the Oxaliplatin Specific Sanofi Scale (OSSS) Criteria Related Paraesthesia/Dysaesthesia) — 14; 11; 6…

Primary: Percentage of Subjects With Therapeutic Cure at 42 Days for All-analysis Population — 2; 1; 3; 0 Participants

Primary: 2-Year Progression-Free Survival — 71 Percentage of Participants (%)

Primary: Number of Participants With Safety- Solicited Symptoms Related to Challenge Administration — 0; 0; 3; 2 Participants

Primary: Percentage of Eyes Achieving a Manifest Refraction Spherical Equivalent (MRSE) Within ± 0.50 D of the Intended Adjustment Target — 78.3; 80.0; 79.2 percentage of eyes

Primary: Cocaine Craving Scale — 4.33; 3.13 Units on a scale

Primary: Overall Response Rate (Complete and Partial Response) — 46 percentage of participants

Primary: Total Drainage Volume Collected Until Drain Removal — 407.45; 595.90 mL

Primary: Time From Baseline to the First Symptom Relapse During the Double-blind Phase — 92; 224 Days — p=0.0010

Primary: Safety: Number of Subjects With Treatment-emergent Adverse Events and Serious Adverse Events — 30; 39; 28; 17 participants

Primary: Overall Rate of Opioid Prescribing — 0.012; 0.013 Proportion of patients

Primary: Tidal Volume of Each Breath Was Measured Using the Same Breathing Mask CPAP Apparatus Combined With Respiratory Monitoring Device Allowing for Simultaneous Recording…